• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Duchenne Muscular Dystrophy

Latest News

All 11 participants in the trial have advanced to the extension portion of the study and are receiving WVE-N531 monthly. | Image credit: OlegKachura - stock.adobe.com
WVE-N531 Shows Functional Benefits, Muscle Damage Reversal in DMD

March 27th 2025

WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients with Duchenne muscular dystrophy (DMD) in the phase 2 FORWARD-53 trial.

Real-world data suggest delandistrogene moxeparvovec is well-tolerated and effective in patients with DMD. | Image credit: natali_mis - stock.adobe.com
Real-World Study Suggests DMD Gene Therapy Is Safe, Effective

March 26th 2025

Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy approved for the treatment of DMD. Image credit: natali_mis - stock.adobe.com
Delandistrogene Moxeparvovec Shows Long-Term Impacts at 3 and 5 Years in DMD

March 21st 2025

Multiparametric qMRI could potentially help differentiate between DMD and BMD early and improve the management of these conditions. | Image credit: megaflopp - stock.adobe.com
MRI Could Aid in Early Differential Diagnosis of DMD, BMD

March 18th 2025

Activities of daily life, education, and employment were areas of difficulty in the transition to adulthood for patients with Duchenne muscular dystrophy or Becker muscular dystrophy. | Image credit: Nana_studio - stock.adobe.com
Survey Explores Needs of Patients With DMD, BMD Transitioning to Adulthood

February 28th 2025

More News

© 2025 MJH Life Sciences
AJMC®
All rights reserved.